|
1
|
Taipale M, Jarosz DF and Lindquist S:
HSP90 at the hub of protein homeostasis: Emerging mechanistic
insights. Nat Rev Mol Cell Biol. 11:515–528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meissner A, Petersenn S, Heidemann HT,
Osterkamp U, Simon R and Schulte HM: Pharmacokinetics of oral
isosorbide-5-mononitrate in patients with ischemic heart failure.
Klin Wochenschr. 69:213–219. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramanathan RK, Trump DL, Eiseman JL,
Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP,
Ramalingam S, et al: Phase I pharmacokinetic-pharmacodynamic study
of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a
novel inhibitor of heat shock protein 90, in patients with
refractory advanced cancers. Clin Cancer Res. 11:3385–3391. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grem JL, Morrison G, Guo XD, Agnew E,
Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM,
et al: Phase I and pharmacologic study of
17-(allylamino)-17-demethoxygeldanamycin in adult patients with
solid tumors. J Clin Oncol. 23:1885–1893. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldman JW, Raju RN, Gordon GA, El-Hariry
I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W,
et al: A first in human, safety, pharmacokinetics, and clinical
activity phase I study of once weekly administration of the Hsp90
inhibitor ganetespib (STA-9090) in patients with solid
malignancies. BMC Cancer. 13:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saif MW, Takimoto C, Mita M, Banerji U,
Lamanna N, Castro J, O'Brien S, Stogard C and Von Hoff D: A phase
1, dose-escalation, pharmacokinetic and pharmacodynamic study of
BIIB021 administered orally in patients with advanced solid tumors.
Clin Cancer Res. 20:445–455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wagner AJ, Chugh R, Rosen LS, Morgan JA,
George S, Gordon M, Dunbar J, Normant E, Grayzel D and Demetri GD:
A phase 1 study of the HSP90 inhibitor retaspimycin hydrochloride
(IPI-504) in patients with gastrointestinal stromal tumors or
soft-tissue sarcomas. Clin Cancer Res. 19:6020–6029. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uozaki H, Ishida T, Kakiuchi C, Horiuchi
H, Gotoh T, Iijima T, Imamura T and Machinami R: Expression of heat
shock proteins in osteosarcoma and its relationship to prognosis.
Pathol Res Pract. 196:665–673. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chiosis G and Neckers L: Tumor selectivity
of Hsp90 inhibitors: The explanation remains elusive. ACS Chem
Biol. 1:279–284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moulick K, Ahn JH, Zong H, Rodina A,
Cerchietti L, Da Gomes Gama EM, Caldas-Lopes E, Beebe K, Perna F,
Hatzi K, et al: Affinity-based proteomics reveal cancer-specific
networks coordinated by Hsp90. Nat Chem Biol. 7:818–826. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garcia-Carbonero R, Carnero A and Paz-Ares
L: Inhibition of HSP90 molecular chaperones: Moving into the
clinic. Lancet Oncol. 14:e358–e369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taldone T, Patel HJ, Bolaender A, Patel MR
and Chiosis G: Protein chaperones: A composition of matter review
(2008-2013). Expert Opin Ther Pat. 24:501–518. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gartner EM, Silverman P, Simon M, Flaherty
L, Abrams J, Ivy P and Lorusso PM: A phase II study of
17-allylamino-17-demethoxygeldanamycin in metastatic or locally
advanced, unresectable breast cancer. Breast Cancer Res Treat.
131:933–937. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Modi S, Stopeck A, Linden H, Solit D,
Chandarlapaty S, Rosen N, D'Andrea G, Dickler M, Moynahan ME,
Sugarman S, et al: HSP90 inhibition is effective in breast cancer:
A phase II trial of tanespimycin (17-AAG) plus trastuzumab in
patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jhaveri K, Chandarlapaty S, Lake D,
Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S,
Wasserheit-Leiblich C, Fasano J, et al: A phase II open-label study
of ganetespib, a novel heat shock protein 90 inhibitor for patients
with metastatic breast cancer. Clin Breast Cancer. 14:154–160.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Modi S, Saura C, Henderson C, Lin NU,
Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J and
Baselga J: A multicenter trial evaluating retaspimycin HCL
(IPI-504) plus trastuzumab in patients with advanced or metastatic
HER2-positive breast cancer. Breast Cancer Res Treat. 139:107–113.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hendrickson AE, Oberg AL, Glaser G,
Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP,
Kaufmann SH, Karnitz LM and Haluska P: A phase II study of
gemcitabine in combination with tanespimycin in advanced epithelial
ovarian and primary peritoneal carcinoma. Gynecol Oncol.
124:210–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Richardson PG, Badros AZ, Jagannath S,
Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M and Anderson
KC: Tanespimycin with bortezomib: Activity in relapsed/refractory
patients with multiple myeloma. Br J Haematol. 150:428–437.
2010.PubMed/NCBI
|
|
19
|
Ronnen EA, Kondagunta GV, Ishill N,
Sweeney SM, Deluca JK, Schwartz L, Bacik J and Motzer RJ: A phase
II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients
with papillary and clear cell renal cell carcinoma. Invest New
Drugs. 24:543–546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Heath EI, Gaskins M, Pitot HC, Pili R, Tan
W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, et al: A phase
II trial of 17-allylamino-17-demethoxygeldanamycin in patients with
hormone-refractory metastatic prostate cancer. Clin Prostate
Cancer. 4:138–141. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oh WK, Galsky MD, Stadler WM, Srinivas S,
Chu F, Bubley G, Goddard J, Dunbar J and Ross RW: Multicenter phase
II trial of the heat shock protein 90 inhibitor, retaspimycin
hydrochloride (IPI-504), in patients with castration-resistant
prostate cancer. Urology. 78:626–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Solit DB, Osman I, Polsky D, Panageas KS,
Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, et
al: Phase II trial of 17-allylamino-17-demethoxygeldanamycin in
patients with metastatic melanoma. Clin Cancer Res. 14:8302–8307.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pacey S, Gore M, Chao D, Banerji U, Larkin
J, Sarker S, Owen K, Asad Y, Raynaud F, Walton M, et al: A Phase II
trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG,
tanespimycin) in patients with metastatic melanoma. Invest New
Drugs. 30:341–349. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cercek A, Shia J, Gollub M, Chou JF,
Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB
and Saltz LB: Ganetespib, a novel Hsp90 inhibitor in patients with
KRAS mutated and wild type, refractory metastatic colorectal
cancer. Clin Colorectal Cancer. 13:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Socinski MA, Goldman J, El-Hariry I,
Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H,
Sequist LV, et al: A multicenter phase II study of
ganetespibmonotherapy in patients with genotypically defined
advanced non-small cell lung cancer. Clin Cancer Res. 19:3068–3077.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sequist LV, Gettinger S, Senzer NN,
Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R,
Hafeez N, et al: Activity of IPI-504, a novel heat-shock protein 90
inhibitor, in patients with molecularly defined non-small-cell lung
cancer. J Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dickson MA, Okuno SH, Keohan ML, Maki RG,
D'Adamo DR, Akhurst TJ, Antonescu CR and Schwartz GK: Phase II
study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal
tumors. Ann Oncol. 24:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chandarlapaty S, Scaltriti M, Angelini P,
Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J
and Rosen N: Inhibitors of HSP90 block p95-HER2 signaling in
Trastuzumab-resistant tumors and suppress their growth. Oncogene.
29:325–334. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Trans Med.
3:75ra262011. View Article : Google Scholar
|
|
30
|
Tillotson B, Slocum K, Coco J, Whitebread
N, Thomas B, West KA, MacDougall J, Ge J, Ali JA, Palombella VJ, et
al: Hsp90 (heat shock protein 90) inhibitor occupancy is a direct
determinant of client protein degradation and tumor growth arrest
in vivo. J Biol Chem. 285:39835–39843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goetz MP, Toft D, Reid J, Ames M,
Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, et
al: Phase I trial of 17-allylamino-17-demethoxygeldanamycin in
patients with advanced cancer. J Clin Oncol. 23:1078–1087. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Banerji U, O'Donnell A, Scurr M, Pacey S,
Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M,
et al: Phase I pharmacokinetic and pharmacodynamic study of
17-allylamino, 17-demethoxygeldanamycin in patients with advanced
malignancies. J Clin Oncol. 23:4152–4161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nowakowski GS, McCollum AK, Ames MM,
Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL and Erlichman
C: A phase I trial of twice-weekly
17-allylamino-demethoxy-geldanamycin in patients with advanced
cancer. Clin Cancer Res. 12:6087–6093. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pratt WB, Morishima Y, Peng HM and Osawa
Y: Proposal for a role of the Hsp90/Hsp70-based chaperone machinery
in making triage decisions when proteins undergo oxidative and
toxic damage. Exp Biol Med (Maywood). 235:278–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Solit DB, Basso AD, Olshen AB, Scher HI
and Rosen N: Inhibition of heat shock protein 90 function
down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer
Res. 63:2139–2144. 2003.PubMed/NCBI
|
